The impact of the COVID-19 pandemic and the changing landscape of CF on the cASPerCF trial: a real-world experience
Trials
.
2024 Oct 2;25(1):645.
doi: 10.1186/s13063-024-08510-1.
Authors
Emily L D Chesshyre
1
2
,
Jacob D Bradbury
1
,
Heather Cook
3
,
Francesca Rocchi
4
,
Kit Roes
5
,
Mark A Turner
6
7
8
,
Roger Brüggemann
5
,
Adilia Warris
9
10
Affiliations
1
MRC Centre for Medical Mycology, University of Exeter, Exeter, UK.
2
Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
3
Clinical Trials Unit, University of Exeter, Exeter, UK.
4
Ospedale Pediatrico Bambino Gesu, Rome, Italy.
5
Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
6
Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
7
Centre for Women's Health Research, Liverpool Women's Hospital, Liverpool, UK.
8
, conect4children Stichting, Utrecht, the Netherlands.
9
MRC Centre for Medical Mycology, University of Exeter, Exeter, UK.
[email protected]
.
10
Great Ormond Street Hospital for Children, London, UK.
[email protected]
.
PMID:
39358818
PMCID:
PMC11446038
DOI:
10.1186/s13063-024-08510-1
No abstract available
Publication types
Letter
MeSH terms
COVID-19* / epidemiology
COVID-19* / prevention & control
Humans
Pandemics
SARS-CoV-2
Treatment Outcome